IL1R1 and type 1 diabetes mellitus: In line with this idea, in 2010 the ITN–JDRF T1D Combination Therapies Assessment Group established a ranking of immune-based combinatory therapies for T1D [109], favoring combinations involving anti-CD3 mAb with antigen-specific (insulin, GAD) or anti-inflammatory (IL-1R/IL-1 blockade) therapies, which can be adjusted depending on the patient’s immune and antigen profile.